Sorafenib augments the therapeutic efficacy of ACT by inhibiting STAT3 expression and downregulating immunosuppressive factors in tumor cells and tumor microenvironment.
figureposted on 2014-10-15, 03:21 authored by Hui-Yen Chuang, Ya-Fang Chang, Ren-Shyan Liu, Jeng-Jong Hwang
Downregulation of immunosuppressive factors, including TGF-β, IL-10, CCL2/MCP-1 and VEGF, lowers the populations of both Tregs and MDSCs. Transferred CD8+ T cells show better activation and killing effects due to declined Tregs and MDSCs. Furthermore, more transferred CD8+ T cells accumulate in tumors and survive longer, so that enhanced therapeutic responses can be achieved.
Read the peer-reviewed publication
tumor inhibitionsSorafenib Enhance Therapeutic Efficacye.gmdscgranzyme B promoterstatSerial Low Dosestumor microenvironmentT cells therapytumor microenvironment limitControversial immunomodulation effectsAccumulating evidences showAdoptive T Cell Therapyt cellssorafenibTumor Microenvironment Requirements